---
document_datetime: 2023-09-21 17:54:14
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/perjeta-epar-all-authorised-presentations_en.pdf
document_name: perjeta-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8706952
conversion_datetime: 2025-12-22 20:40:32.996522
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) Number   | (Invented) name   | Strength   | Pharmaceutical Form                   | Route of Administration   | Packaging    | Content (concentration)   | Package size   |
|------------------|-------------------|------------|---------------------------------------|---------------------------|--------------|---------------------------|----------------|
| EU/1/13/813/001  | Perjeta           | 420 mg     | Concentrate for solution for infusion | Intravenous use           | Vial (glass) | 30 mg/ml                  | 1 vial         |